Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international bv - asagly-nafareliin - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - dogs; salmonidae (salmonid fish) - naine salmonid kalade, nagu lõhe (salmo salar), vikerforell (oncorhynchus mykiss), jõeforelli (salmo trutta) ja arktika charr (salvelinus alpinus)esilekutsumine ja sünkroonimine ovulatsiooni tootmiseks eyed-muna ja praadida. koerad (emased)ennetamine gonadal funktsiooni emased kaudu pikaajalise blokaadi gonadotropiini süntees.

Eesti - eesti - Ravimiamet

laboratorio sanderson s.a - kaltsiumglükonaat - süstelahus - 100mg 1ml 10ml 100tk

Eesti - eesti - Ravimiamet

s.a.l.f. s.p.a. laboratorio farmacologico - kaltsiumglükonaat - infusioonilahus - 100mg 1ml 10ml 5tk

Eesti - eesti - Ravimiamet

jsc kievmedpreparat"" - kaltsiumglükonaat - tablett - 500mg 10tk

Eesti - eesti - Ravimiamet

oao monfarm - kaltsiumglükonaat - tablett - 500mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Eesti - eesti - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 600mg 20tk; 600mg 90tk; 600mg 200tk; 600mg 60tk; 600mg 30tk; 600mg 100tk; 600mg 10tk; 600mg 50tk

Eesti - eesti - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 300mg 200tk; 300mg 60tk; 300mg 90tk; 300mg 20tk; 300mg 10tk; 300mg 30tk; 300mg 50tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant võib kasutada monoteraapiana või kombinatsioonis metotreksaadiga. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.